利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.044 秒)

    Therapeutic morpholino-substituted compounds
    2.
    发明申请
    Therapeutic morpholino-substituted compounds 失效
    治疗性吗啉取代的化合物

    公开(公告)号：US20050085471A1

    公开(公告)日：2005-04-21

    申请号：US10961062

    申请日：2004-10-12

    申请人： Alan Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K9/02 ,  A61K9/08 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/5377 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/04 ,  A61P37/06 ,  A61P43/00 ,  C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04 ,  C07D413/04

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    摘要翻译： 吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。 因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。 所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。 因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。 该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病，包括癌症如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌的肿瘤，以及与无序白细胞功能如自身免疫性和炎性疾病相关的疾病。

    Therapeutic morpholino-substituted compounds
    3.
    发明授权
    Therapeutic morpholino-substituted compounds 失效
    治疗性吗啉取代的化合物

    公开(公告)号：US06977255B2

    公开(公告)日：2005-12-20

    申请号：US10181485

    申请日：2001-01-24

    申请人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yap ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yap ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K9/02 ,  A61K9/08 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/5377 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/04 ,  A61P37/06 ,  A61P43/00 ,  C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04 ,  A61K31/352

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    摘要翻译： 吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。 因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。 所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。 因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。 该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 包括诸如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌等癌症的肿瘤，以及与无序白细胞功能相关的疾病，例如自身免疫性和炎性疾病。

    Therapeutic Morpholino-Substituted Compounds
    4.
    发明申请
    Therapeutic Morpholino-Substituted Compounds 失效
    治疗性吗啉取代的化合物

    公开(公告)号：US20080206312A1

    公开(公告)日：2008-08-28

    申请号：US12019061

    申请日：2008-01-24

    申请人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K31/5377 ,  C07D413/04 ,  A61K9/12 ,  A61K47/06 ,  A61P9/00 ,  A61P11/00 ,  A61P35/04 ,  A61P7/00

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    摘要翻译： 吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。 因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。 所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。 因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。 该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 肿瘤包括癌症，如胶质瘤，前列腺癌，小细胞肺癌和乳腺癌; 以及与无序白细胞功能相关的疾病，如自身免疫性疾病和炎性疾病。

    Therapeutic Morpholino-Substituted Compounds
    5.
    发明申请
    Therapeutic Morpholino-Substituted Compounds 审中-公开

    公开(公告)号：US20080312233A1

    公开(公告)日：2008-12-18

    申请号：US12115563

    申请日：2008-05-06

    申请人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K31/5377 ,  A61P11/00 ,  A61P9/00

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    Therapeutic morpholino-substituted compounds
    6.
    发明授权
    Therapeutic morpholino-substituted compounds 失效
    治疗性吗啉取代的化合物

    公开(公告)号：US07405211B2

    公开(公告)日：2008-07-29

    申请号：US10961062

    申请日：2004-10-12

    申请人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K31/5377 ,  C07D413/04

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    摘要翻译： 吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。 因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。 所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。 因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。 该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病，包括癌症如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌的肿瘤，以及与无序白细胞功能如自身免疫性和炎性疾病相关的疾病。

    Therapeutic morpholino-substituted compounds
    7.
    发明授权
    Therapeutic morpholino-substituted compounds 失效
    治疗性吗啉取代的化合物

    公开(公告)号：US07572791B2

    公开(公告)日：2009-08-11

    申请号：US12019061

    申请日：2008-01-24

    申请人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K31/5375 ,  C07D413/02

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    摘要翻译： 吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。 因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。 所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。 因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。 该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 肿瘤包括癌症，如胶质瘤，前列腺癌，小细胞肺癌和乳腺癌; 以及与无序白细胞功能相关的疾病，如自身免疫性疾病和炎性疾病。

    In-case computer charging system
    9.
    发明申请
    In-case computer charging system 审中-公开
    机箱电脑充电系统

    公开(公告)号：US20060289444A1

    公开(公告)日：2006-12-28

    申请号：US11441586

    申请日：2006-05-26

    申请人： Shaun Jackson ,  Mark Zadvinskis

    发明人： Shaun Jackson ,  Mark Zadvinskis

    IPC分类号： F27D11/00

    CPC分类号： B64D15/12 ,  B32B5/024 ,  B32B5/12 ,  B32B5/26 ,  B32B2250/03 ,  B32B2250/20 ,  B32B2250/40 ,  B32B2255/02 ,  B32B2255/205 ,  B32B2260/023 ,  B32B2260/046 ,  B32B2262/101 ,  B32B2262/106 ,  B32B2307/54 ,  B32B2603/00 ,  G06F1/1628 ,  G06F1/1632 ,  H05B3/347 ,  H05B2203/007 ,  H05B2203/014 ,  H05B2203/017

    摘要： A case configured to enclose a portable electronic device includes a plurality of externally accessible electrical contacts, enabling electrical current to flow to or from the device while enclosed in the case. The invention is applicable to all types of portable devices, including laptop, notebook and palm-top computers, as well as telecommunications devices, video players and music players. Typically the electrical contacts allow a battery in the case or in the device to be recharged while device is enclosed. An adaptor cable may be provided between the device and the electrical contacts so that the same or similar case may be used with different model devices from different manufacturers. For greater ‘universality,’ a voltage-changing adaptor cable may be provided within the case between the device and the electrical contacts. The system may further include a docking bay to receive the case, the docking bay having a set of electrical contacts configured to electrically engage with the contacts on the case. Such a docking bay may take the form of a charging stand, a cart with one or more slots or compartments, or a locker with a door and a storage compartment.

    摘要翻译： 被配置为封闭便携式电子设备的壳体包括多个可外部访问的电触头，使得电流能够流入或流出设备，同时封闭在外壳中。 本发明适用于所有类型的便携式设备，包括笔记本电脑，笔记本电脑和掌上电脑以及电信设备，视频播放器和音乐播放器。 通常，电触点允许在封装设备的情况下或在设备中的电池被充电。 可以在设备和电触点之间提供适配器电缆，使得可以使用与不同制造商的不同型号的设备相同或相似的情况。 为了获得更大的“通用性”，可以在设备和电气触点之间的壳体内提供电压改变的适配器电缆。 该系统还可以包括用于容纳壳体的对接舱，该对接舱具有一组电触点，其被配置为与壳体上的触点电接合。 这样的对接托架可以采取充电架，具有一个或多个槽或隔间的推车，或具有门和储物室的储物柜的形式。